Replies to post #189397 on Biotech Values

[DewDiligence]

For #1, check the Xgeva dossier. There may have been an Xgeva trial where the time to a second skeletal event was the primary or co-primary endpoint.

[biomaven0]

>>time to event trial designs

Interesting idea, but it potentially will reduce the power a lot because you will have fewer events. So either going to need a very big trial, or an indication with lots of multiple events.

Peter